Jane X. Liu

Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.

J. Williams, C. Blackburn, M. Duffey, 2010, Bioorganic & medicinal chemistry letters.

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.

M. Rolfe, A. Berger, Jie Yu, 2010, Cancer research.

Characterization of a New Series of Non-covalent Proteasome Inhibitors with Exquisite Potency and Selectivity for the 20s Β5-subunit Figure S1 Activities of Compound 1 and Bortezomib in Cells

T. Soucy, E. Olhava, M. Sintchak, 2010 .

Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome

M. Sintchak, L. Dick, J. Blank, 2012 .

Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

Jonathan L Blank, Christopher Tsu, Christopher Blackburn, 2010, Bioorganic & medicinal chemistry letters.

Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.

S. Langston, K. Garcia, C. Blackburn, 2010, Bioorganic & medicinal chemistry letters.

Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.

Yuan Tian, Hongbo Zeng, Mansoureh Rezaei, 2011, Journal of medicinal chemistry.

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit

T. Soucy, E. Olhava, M. Sintchak, 2010, The Biochemical journal.